Akebia Initiates Patient Dosing In AKB-6548 Phase 1b Trial
The Phase 1a study of AKB-6548 has demonstrated a dose-related increase in erythropoietin with no significant adverse events. Akebia said that the Phase 1b study is designed to
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.
Meditel uses Global Cardio 3-Lead to record patient electrocardiograms (ECGs), create ECG reports and distribute those reports to the patient’s physician. Federico Vago, technical and operational manager at